Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]-Lasmiditan in Healthy Subjects
NCT03040362Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lasmiditan in migraine, sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Plasma Concentration at 192 hours, Time of Maximum Observed Plasma Concentration at 192 hours and 3 more. Started Apr 2017; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03040362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040362.